Bengaluru-based MedGenome is offering Adaptive Biotechnologies’ next-generation sequencing (NGS)-based clonoSEQ Assay to assess minimal residual disease (MRD) in patients with multiple myeloma (MM), chronic lymphocytic leukaemia (CLL) and B-cell acute lymphoblastic leukaemia (B-ALL).  

The clonoSEQ test may effectively detect and monitor MRD in patients with certain types of blood cancer. It helps to detect MRD even at low levels offering a prognostic value to clinicians, helping them to assess how patients respond to treatment or if any change in disease management is required.

The test determines MRD at very low levels (10-6 sensitivity) as compared to other currently available assays for MRD detection and therefore imparts a benefit to a larger number of patients. The test identifies dominant immune cell clones at the time of high disease burden that can be monitored after the treatment to determine MRD.